End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma.

MLA

Jacobson, Caron A., et al. “End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma.” Biology of Blood & Marrow Transplantation, vol. 25, no. 3, Mar. 2019, p. S173. EBSCOhost, https://doi.org/10.1016/j.bbmt.2018.12.314.

APA

Jacobson, C. A., Locke, F. L., Miklos, D. B., Herrera, A. F., Westin, J. R., Lee, J., Rossi, J. M., Sun, J., Zheng, L., Avanzi, M. P., & Roberts, Z. J. (2019). End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. Biology of Blood & Marrow Transplantation, 25(3), S173. https://doi.org/10.1016/j.bbmt.2018.12.314

Chicago

Jacobson, Caron A., Frederick L. Locke, David B. Miklos, Alex F. Herrera, Jason R. Westin, Jennifer Lee, John M. Rossi, et al. 2019. “End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma.” Biology of Blood & Marrow Transplantation 25 (3): S173. doi:10.1016/j.bbmt.2018.12.314.